Lancet Gastroenterology & Hepatology最新文献

筛选
英文 中文
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease 肠系膜保留或扩大切除在克罗恩病原发回肠结肠切除术中的应用
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00343-1
Matthias Kelm, Sven Flemming
{"title":"Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease","authors":"Matthias Kelm, Sven Flemming","doi":"10.1016/s2468-1253(24)00343-1","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00343-1","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"9 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Action on ultra-processed foods needs robust evidence 对超加工食品采取行动需要强有力的证据
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00405-9
{"title":"Action on ultra-processed foods needs robust evidence","authors":"","doi":"10.1016/s2468-1253(24)00405-9","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00405-9","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"14 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut Reaction 本能反应
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00394-7
Fio Trethewey
{"title":"Gut Reaction","authors":"Fio Trethewey","doi":"10.1016/s2468-1253(24)00394-7","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00394-7","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"4 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction—What is normal and abnormal in lactose digestion? 缩回——什么是乳糖消化的正常和异常?
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00399-6
{"title":"Retraction—What is normal and abnormal in lactose digestion?","authors":"","doi":"10.1016/s2468-1253(24)00399-6","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00399-6","url":null,"abstract":"In this Comment,<span><span><sup>1</sup></span></span> the authors cite and interpret data based on an Article we now know to be unreliable and that has now been retracted.<span><span><sup>2</sup></span></span> The Committee on Publication Ethics advises that, in such circumstances, the linked Comment should also be retracted to avoid any misunderstanding among readers. We are therefore retracting this Comment.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"11 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease – Authors’ reply 肠系膜保留或扩大切除在克罗恩病原发回结肠切除术中的应用——作者的答复
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00383-2
Eline M L van der Does de Willebois, Willem A Bemelman, Christianne J Buskens
{"title":"Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease – Authors’ reply","authors":"Eline M L van der Does de Willebois, Willem A Bemelman, Christianne J Buskens","doi":"10.1016/s2468-1253(24)00383-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00383-2","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"179 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis 强化英夫利昔单抗诱导治疗类固醇难治性急性严重溃疡性结肠炎
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00379-0
Yannick Hoffert, Marc Ferrante, Bram Verstockt, Erwin Dreesen
{"title":"Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis","authors":"Yannick Hoffert, Marc Ferrante, Bram Verstockt, Erwin Dreesen","doi":"10.1016/s2468-1253(24)00379-0","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00379-0","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"1 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Gastroenterol Hepatol 2024; 9: 774–75 《柳叶刀Gastroenterol Hepatol 2024》修正;9: 774 - 75
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00400-x
{"title":"Correction to Lancet Gastroenterol Hepatol 2024; 9: 774–75","authors":"","doi":"10.1016/s2468-1253(24)00400-x","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00400-x","url":null,"abstract":"<em>Click B, Holubar SD. Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?</em> Lancet Gastroenterol Hepatol <em>2024;</em> 9: <em>774–75</em>—In this Comment, the last sentence of the third paragraph should read “While previously described extended mesenteric excision approaches incorporate a high ligation of the ileocolic pedicle, van der Does de Willebois and colleagues assess a modified approach that spares the ileocolic trunk.” The first sentence of the fourth paragraph should read “In the SPICY trial, a total of 139 surgically-naive patients with ileal or ileocolonic Crohn's disease were randomly assigned to either extended mesenteric excision sparing the ileocolic trunk or a traditional side-to-side anastomosis with a mesenteric sparing approach.” The second sentence of the last paragraph should read “Furthermore, whether the extended mesenteric excision approach in SPICY, which spares the ileocolic trunk, differs from an approach that takes the trunk is unknown and deserves exploration.” These corrections have been made to the online version as of Dec 11, 2024.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"239 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease 肠系膜保留或扩大切除在克罗恩病原发回肠结肠切除术中的应用
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00344-3
Ming Duan, Yi Li
{"title":"Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease","authors":"Ming Duan, Yi Li","doi":"10.1016/s2468-1253(24)00344-3","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00344-3","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"82 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Liver Meeting 2024 2024年肝脏会议
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00392-3
Rob Brierley
{"title":"The Liver Meeting 2024","authors":"Rob Brierley","doi":"10.1016/s2468-1253(24)00392-3","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00392-3","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Semaglutide for MASH</h2>Semaglutide 2·4 mg once a week demonstrated significantly greater improvements in histology and fibrosis than did placebo in participants with metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, according to data from the phase 3 ESSENCE trial. Although the trial is ongoing, Phil Newsome (London, UK) presented data from the prespecified interim analysis at week 72 of the first 800 participants, of whom 534 had been randomly assigned to receive semaglutide and 266 had</section></section><section><section><h2>Optimising steroid use in severe alcohol-associated hepatitis</h2>Tapering the dose of corticosteroids is safer and just as efficacious as conventional fixed-dose corticosteroids for severe alcohol-associated hepatitis, according to results from the STASH trial, presented by Anand Kulkarni (Hyderabad, India). Patients with severe alcohol-associated hepatitis were randomly assigned to receive either a fixed-dose or tapering regimen. Patients in each group initially received 40 mg prednisolone a day for 7 days. Patients in the fixed dose group with a Lille</section></section><section><section><h2>CM-101 in primary sclerosing cholangitis</h2>CM-101, an anti-CCL24 monoclonal antibody, exhibited promising activity in patients with primary sclerosing cholangitis and had a safety profile similar to placebo, according to data from the phase 2 SPRING study. In this placebo-controlled trial, presented by Christopher Bowlus (Davis, CA, USA), patients with primary sclerosing cholangitis were randomly assigned to receive either CM-101 at 10 mg/kg (n=25), CM-101 at 20 mg/kg (n=31), or placebo (n=21) every 3 weeks for 15 weeks.</section></section><section><section><h2>VK2809 for steatotic liver disease</h2>The phase 2b VOYAGE trial examined the use of VK2809, a small molecule thyroid hormone receptor beta agonist prodrug that is selectively cleaved in hepatic tissue by cytochrome P450 3A4 to release a pharmacologically active metabolite, in individuals with biopsy-confirmed non-alcoholic fatty liver disease and fibrosis. Participants were randomly assigned to receive placebo or VK2809 at 1 mg/day, 2·5 mg/day, 5 mg/day, or 10 mg/day. Percentage change in MRI-PDFF at 3 months was –56·7% in the</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"29 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Gastroenterol Hepatol 2024; 9: 718–33 《柳叶刀Gastroenterol Hepatol 2024》修正;9: 718 - 33所示
IF 35.7 1区 医学
Lancet Gastroenterology & Hepatology Pub Date : 2024-12-11 DOI: 10.1016/s2468-1253(24)00401-1
{"title":"Correction to Lancet Gastroenterol Hepatol 2024; 9: 718–33","authors":"","doi":"10.1016/s2468-1253(24)00401-1","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00401-1","url":null,"abstract":"<em>Janssen HLA, Lim Y-S, Lampertico P, et al. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.</em> Lancet Gastroenterol Hepatol <em>2024;</em> 9: <em>718–33</em>—In this Article, the label for previous other oral antiviral in figure 3B should have read 0·04; the label for previous tenofovir disproxil fumarate in figure 4C should have read 1·09%; and the label for tenofovir alafenamide in figure 4C should have read 0·28%. These corrections have been made to the online version as of Dec 11, 2024.","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"538 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信